FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Special Reports

Emerging Drug Developer: Rexahn Pharmaceuticals

Rexahn turns to deal-making as Phase II results loom Over the course of its eight-year history, Rexahn Pharmaceuticals' rep was been built primarily around its successful advancement of three key

Read more >>

CEO pay of 2008: Who makes what in Big Biotech?

by Maureen Martino and Calisha Myers Last month we brought you a list of the top 15 Pharma CEO Paychecks. And as promised, here's a look at the five highest-paid CEOs in the biotech industry. This

Read more >>

Emerging Drug Developer: Bayhill Therapeutics

Bayhill turns to deal-making to fund its growth Mark Schwartz, PhD, doesn't like the idea of ranking Bayhill Therapeutics' two clinical programs. "We're working on a very innovative and new

Read more >>

Emerging Drug Developer: Clovis Oncology

A proven team gets $145M to take a familiar path Patrick Mahaffy thinks he has a pretty good business plan for his start-up biotech company. Gather an experienced biotech team, raise $145 million in

Read more >>

Emerging Drug Developer: Tokai Pharmaceuticals

Tokai Pharmaceuticals Seth Harrison knows a thing or two about jump-starting a biotech company without busting the bank. As managing general partner at Apple Tree Partners, he's had the opportunity

Read more >>

Emerging Drug Developer: VaxInnate

VaxInnate breaks a new path in vaccine development The global alarm sounding over the outbreak of a new strain of H1N1 has once again highlighted just how inefficient the vaccine industry is. Using

Read more >>

Top 5 Regions Targeting Biotech Companies - 2009

Economic development programs have always played an important role in boosting the U.S. biotech industry. When a company has to invest years and millions of dollars just to get started, it needs

Read more >>

Top 15 Big Pharma Paychecks of 2008

by Maureen Martino and Calisha Myers Welcome to to our second annual look at pharma CEO salaries. Every year, executive salaries cause a flap as industry watchers compare who makes what, who got a

Read more >>

Emerging Drug Developer: Altor BioScience

Altor BioScience readies itself for Phase II To understand Altor BioScience's niche in the cancer field, you need to take a look at its lead program: ALT-801. Researchers took a cancer therapy, IL-2,

Read more >>